Atyr PHARMA INC (NASDAQ:ATYR) Director Paul Schimmel Acquires 52,300 Shares

Atyr PHARMA INC (NASDAQ:ATYR) Director Paul Schimmel purchased 52,300 shares of the firm’s stock in a transaction dated Wednesday, July 24th. The stock was acquired at an average cost of $1.93 per share, with a total value of $100,939.00. Following the purchase, the director now owns 413,023 shares of the company’s stock, valued at approximately $797,134.39. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Paul Schimmel also recently made the following trade(s):

• On Monday, July 22nd, Paul Schimmel purchased 41,052 shares of Atyr PHARMA stock. The stock was acquired at an average cost of $1.74 per share, with a total value of $71,430.48.

Atyr PHARMA Trading Up 3.2 %

ATYR stock traded up $0.06 during trading hours on Wednesday, hitting $1.93. 690,854 shares of the stock traded hands, compared to its average volume of 482,231. Atyr PHARMA INC has a one year low of $1.08 and a one year high of $2.15. The stock has a market capitalization of $133.19 million, a P/E ratio of -2.17 and a beta of 1.25. The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.02.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $35.00 price target on shares of Atyr PHARMA in a research note on Monday.

Atyr PHARMA Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company’s lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.